Our Mission
SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our unique platform
Nevisense
The unique Nevisense platform utilizes advanced EIS- technology combined with AI to empower healthcare professionals by improving diagnostic accuracy, enabling disease monitoring, and facilitating early detection of skin cancer. The Nevisense procedure is non-invasive and provides clinicians with objective and actionable data, at point-of-care. It has been developed based on 20+ years of research from the Karolinska Institute and several years of clinical experience.
Read more
News
Events
SciBase announces outcome in the directed issue of units
May 13, 2024On 5 April 2024 SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's board of directors resolved, subject to subsequent approval by the general meeting, on directed issues of a total of 77,891,769 units consisting of shares and warrants of series TO 2, with deviation from the shareholders preferential rights, to a total approximate amount of SEK 33 million (the "Directed Issue"). The subscription price in the Directed Issue amounted to SEK 0.42 per unit, corresponding to SEK 0.42 per share. The extraordinary general meeting on 13 May 2024 resolved to approve the Directed Issue. All units in the Directed Issue have been subscribed and the board of directors has therefore today, on 13 May 2024, resolved on allotment of all units in the Directed Issue.
Bulletin from the extraordinary general meeting in SciBase Holding AB (publ)
Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance with the proposals presented in the notice to attend the meeting (which is available on the Company's website (www.scibase.com)):
SciBase announces outcome in rights issue of units
May 10, 2024The Board of Directors in SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome in the rights issue of so called units, consisting of shares and warrants of series TO 2 ("Units"), with preferential rights for the Company's existing shareholders of approximately SEK 15 million which was resolved upon by the Board of Directors on 5 April 2024 by virtue of the authorization from the annual general meeting on 17 May 2023 (the "Rights Issue"). The subscription price in the Rights Issue was SEK 0.42 per Unit, corresponding to SEK 0.42 per share. The warrants of series TO 2 are issued free of charge. The subscription period in the Rights Issue ended on 7 May 2024. 13,264,074 Units were subscribed for with support of unit rights, corresponding to approximately 37 percent of the Rights Issue. 8,493,194 Units, corresponding to approximately 24 percent of the Rights Issue, have been allotted to persons who have subscribed for Units without support of unit rights. In total, 21,757,268 Units were subscribed for in the Rights Issue, corresponding to approximately 61 percent of the Rights Issue. Through the Rights Issue, the Company will initially receive proceeds of approximately SEK 9 million before deduction of transaction costs. If all warrants of series TO 2 issued in the Rights Issue are exercised for subscription of shares the Company will receive additional proceeds of approximately SEK 46 million before deduction of transaction costs.
- Load more news...
News
We follow
Our commitment
At SciBase we stay true to our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention at the first signs of skin diseases and to reduce healthcare costs.
Skin Barrier Assessment
For Atopic Dermatitis
Nevisense is a unique, AI-based platform for the non-invasive, assessment of the skin barrier function. The measurements provide researchers with objective and actionable data at point-of-care. Nevisense provides healthcare professionals with the ability to monitor therapeutic improvements and disease progression, while detect non-visual and subclinical inflammation.